DSAM Partners’s Kronos Bio KRON Stock Holding History

DSAM Partners’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-177,426	Closed	-$5.19M	–	49
2021 Q1	$5.19M	Sell	177,426 -22,670	-11%	-$664K	0.96%	28
2020 Q4	$5.98M	Buy	+200,096	New	+$6.28M	0.7%	41

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DSAM Partners's KRON Position: Q2 2021 in Review

DSAM Partners sold out of Kronos Bio (KRON) in Q2 2021, closing a stake of 177,426 shares — an estimated $5.19M sold.

DSAM Partners first reported a position in KRON in Q4 2020 and held it in 2 quarters. The position peaked at $5.98M in Q4 2020. 77 funds tracked by Wall St. Rank hold KRON as of Q2 2021.

DSAM Partners reported no remaining Kronos Bio position as of Q2 2021 after selling out during the quarter.
DSAM Partners sold 177,426 Kronos Bio shares in Q2 2021, an estimated $5.19M.
DSAM Partners first reported a position in Kronos Bio in Q4 2020 and held it in 2 quarters.
DSAM Partners's Kronos Bio position peaked at $5.98M in Q4 2020.
77 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2021.

Based on DSAM Partners's 13F filing for Q2 2021, filed 16 Aug 2021.